Study 22143
A Phase 1 Open-label, First-in-human, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Actinium-225-macropa-pelgifatamab (BAY 3546828) in Participants With Advanced Metastatic Castration Resistant Prostate Cancer (mCRPC) Nature and ObjectiveThis Phase 1, first-in-human study investigates the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of actinium-225-macropa-pelgifatamab (BAY3546828) in individuals with advanced metastatic castration-resistant […]
OMAHA-004
MK-5684-004: A Phase 3, Randomized, Open-label Study of Opevesostat Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA) (OMAHA-004) Nature and Objective:This Phase 3 study evaluates the efficacy and safety of opevesostat (MK-5684), a CYP11A1 inhibitor, combined […]
MK-5684-01A Substudy
MK-5684-01A Substudy: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Nature and Objective:MK-5684-01A substudy aims to evaluate the safety, tolerability, and preliminary efficacy of opevesostat (MK-5684), a CYP11A1 inhibitor, administered alone or in […]
MEVPRO-1
A Phase 3, Randomized, Open-Label Study Of Pf-06821497 (Mevrometostat) In Combination With Enzalutamide Compared With Enzalutamide Or Docetaxel In Participants With Metastatic Castration Resistant Prostate Cancer Previously Treated With Abiraterone Acetate (MEVPRO-1) Nature and Objective:The MEVPRO-1 study investigates the efficacy of mevrometostat (PF-06821497), an oral inhibitor of EZH2, in combination with enzalutamide, in patients with […]
MEVPRO-2
A Phase 3, Randomized, Double Blind, Placebo Controlled Study of PF-06821497 (mevrometostat) with Enzalutamide in Metastatic Castration Resistant Prostate Cancer (MEVPRO-2) Nature and Objective:This Phase I/II open-label, multi-center trial aims to evaluate the safety, tolerability, and anti-tumor activity of [225Ac]Ac-PSMA-R2—a targeted radioligand therapy—in adult men with PSMA-positive metastatic prostate cancer. The study includes patients with […]
SatisfACtion
SatisfACtion: Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With mHSPC and Heavily Pre-treated PSMA-positive mCRPC, With/Without Prior 177Lu-labelled PSMA-targeted Radioligand Therapy. Nature et Objectif:This Phase I/II open-label, multi-center trial aims to evaluate the safety, tolerability, and anti-tumor activity of [225Ac]Ac-PSMA-R2—a targeted radioligand therapy—in adult men with PSMA-positive metastatic prostate cancer. The study includes […]
EvoPar
Double-blind, placebo-controlled, randomized, two-cohort phase III study to evaluate AZD5305 A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician’s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01) Nature et objective :This is a research project to determine whether the study drug “AZD5305”, given in […]
PROSTEP-002
Detection and monitoring of metastases using PET/CT imaging using the 18F-DCFPyL (PyL) tracer, in patients starting enzalutamide to treat castration-resistant prostate cancer with small number of metastases, an equivocal result or no metastases on conventional imaging (PROSTEP-002). Nature and objective :This is a study for patients with castration-resistant prostate cancer with a small number of metastases. […]